Tags

Type your tag names separated by a space and hit enter

Plasma Extracellular Vesicle α-Synuclein Level in Patients with Parkinson's Disease.
Biomolecules. 2021 05 17; 11(5)B

Abstract

BACKGROUND

The most established pathognomonic protein of Parkinson's disease (PD), α-synuclein, is extensively investigated for disease diagnosis and prognosis; however, investigations into whether the free form of α-synuclein in the blood functions as a PD biomarker have not been fruitful. Extracellular vesicles (EVs) secreted from cells and present in blood transport molecules are novel platforms for biomarker identification. In blood EVs, α-synuclein originates predominantly from the brain without the interference of the blood-brain barrier. The present study investigated the role of plasma EV-borne α-synuclein as a biomarker of PD.

METHODS

Patients with mild to moderate stages of PD (n = 116) and individuals without PD (n = 46) were recruited to serve as the PD study group and the control group, respectively. Plasma EVs were isolated, and immunomagnetic reduction-based immunoassay was used to assess EV α-synuclein levels. Conventional statistical analysis was performed using SPSS 25.0, and p < 0.05 was considered significant.

RESULTS

Compared with controls, we observed significantly lower plasma EV α-synuclein levels in the patients with PD (PD: 56.0 ± 3.7 fg/mL vs. control: 74.5 ± 4.3 fg/mL, p = 0.009), and the significance remained after adjustment for age and sex. Plasma EV α-synuclein levels in the patients with PD did not correlate with age, disease duration, Part I and II scores of the Unified Parkinson's Disease Rating Scale (UPDRS), or the Mini-Mental State Examination scores. However, such levels were significantly correlated with UPDRS Part III score, which assesses motor dysfunction. Furthermore, the severity of akinetic-rigidity symptoms, but not tremor, was inversely associated with plasma EV α-synuclein level.

CONCLUSION

Plasma EV α-synuclein was significantly different between the control and PD group and was associated with akinetic-rigidity symptom severity in patients with PD. This study corroborates the possible diagnostic and subtyping roles of plasma EV α-synuclein in patients with PD, and it further provides a basis for this protein's clinical relevance and feasibility as a PD biomarker.

Authors+Show Affiliations

Department of Neurology, Taipei Medical University-Shuang Ho Hospital, New Taipei City 23561, Taiwan. Department of Neurology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan. Graduate Institute of Biomedical Informatics, Taipei Medical University, Taipei 11031, Taiwan.Department of Neurology, Taipei Medical University-Shuang Ho Hospital, New Taipei City 23561, Taiwan. Department of Neurology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan.Department of Neurology, Taipei Medical University-Shuang Ho Hospital, New Taipei City 23561, Taiwan.Department of Neurosurgery, Department of Surgery, Chi-Mei Medical Center, Tainan 71004, Taiwan. Department of Recreation and Healthcare Management, Chia Nan University of Pharmacy and Science, Tainan 71710, Taiwan.Department of Neurology, Taipei Medical University-Shuang Ho Hospital, New Taipei City 23561, Taiwan. Department of Neurology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

34067663

Citation

Chung, Chen-Chih, et al. "Plasma Extracellular Vesicle α-Synuclein Level in Patients With Parkinson's Disease." Biomolecules, vol. 11, no. 5, 2021.
Chung CC, Chan L, Chen JH, et al. Plasma Extracellular Vesicle α-Synuclein Level in Patients with Parkinson's Disease. Biomolecules. 2021;11(5).
Chung, C. C., Chan, L., Chen, J. H., Hung, Y. C., & Hong, C. T. (2021). Plasma Extracellular Vesicle α-Synuclein Level in Patients with Parkinson's Disease. Biomolecules, 11(5). https://doi.org/10.3390/biom11050744
Chung CC, et al. Plasma Extracellular Vesicle α-Synuclein Level in Patients With Parkinson's Disease. Biomolecules. 2021 05 17;11(5) PubMed PMID: 34067663.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Plasma Extracellular Vesicle α-Synuclein Level in Patients with Parkinson's Disease. AU - Chung,Chen-Chih, AU - Chan,Lung, AU - Chen,Jia-Hung, AU - Hung,Yi-Chieh, AU - Hong,Chien-Tai, Y1 - 2021/05/17/ PY - 2021/04/06/received PY - 2021/05/12/revised PY - 2021/05/15/accepted PY - 2021/6/2/entrez PY - 2021/6/3/pubmed PY - 2021/9/22/medline KW - Parkinson’s disease KW - akinetic-rigidity KW - extracellular vesicles KW - α-synuclein JF - Biomolecules JO - Biomolecules VL - 11 IS - 5 N2 - BACKGROUND: The most established pathognomonic protein of Parkinson's disease (PD), α-synuclein, is extensively investigated for disease diagnosis and prognosis; however, investigations into whether the free form of α-synuclein in the blood functions as a PD biomarker have not been fruitful. Extracellular vesicles (EVs) secreted from cells and present in blood transport molecules are novel platforms for biomarker identification. In blood EVs, α-synuclein originates predominantly from the brain without the interference of the blood-brain barrier. The present study investigated the role of plasma EV-borne α-synuclein as a biomarker of PD. METHODS: Patients with mild to moderate stages of PD (n = 116) and individuals without PD (n = 46) were recruited to serve as the PD study group and the control group, respectively. Plasma EVs were isolated, and immunomagnetic reduction-based immunoassay was used to assess EV α-synuclein levels. Conventional statistical analysis was performed using SPSS 25.0, and p < 0.05 was considered significant. RESULTS: Compared with controls, we observed significantly lower plasma EV α-synuclein levels in the patients with PD (PD: 56.0 ± 3.7 fg/mL vs. control: 74.5 ± 4.3 fg/mL, p = 0.009), and the significance remained after adjustment for age and sex. Plasma EV α-synuclein levels in the patients with PD did not correlate with age, disease duration, Part I and II scores of the Unified Parkinson's Disease Rating Scale (UPDRS), or the Mini-Mental State Examination scores. However, such levels were significantly correlated with UPDRS Part III score, which assesses motor dysfunction. Furthermore, the severity of akinetic-rigidity symptoms, but not tremor, was inversely associated with plasma EV α-synuclein level. CONCLUSION: Plasma EV α-synuclein was significantly different between the control and PD group and was associated with akinetic-rigidity symptom severity in patients with PD. This study corroborates the possible diagnostic and subtyping roles of plasma EV α-synuclein in patients with PD, and it further provides a basis for this protein's clinical relevance and feasibility as a PD biomarker. SN - 2218-273X UR - https://www.unboundmedicine.com/medline/citation/34067663/Plasma_Extracellular_Vesicle_α_Synuclein_Level_in_Patients_with_Parkinson's_Disease_ L2 - https://www.mdpi.com/resolver?pii=biom11050744 DB - PRIME DP - Unbound Medicine ER -